Δ9Tetrahydrocannabinol attenuates Staphylococcal enterotoxin B-induced inflammatory lung injury and prevents mortality in mice by modulation of miR-17-92 cluster and induction of T-regulatory cells

British Journal of Pharmacology

Volumn 172, Issue 7, 2015, Pages 1792-1806

  Rao, R ^a   Nagarkatti, P S ^a   Nagarkatti, Mitzi ^a  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11 HYDROXYDRONABINOL; MICRORNA; MICRORNA 17 92; MICRORNA 18A; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLACEBO; PROTEIN KINASE B; STAPHYLOCOCCUS ENTEROTOXIN B; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; CYTOKINE; DRONABINOL; ENTEROTOXIN; ENTEROTOXIN B, STAPHYLOCOCCAL; MIRN17-92 MICRORNA, MOUSE; PTEN PROTEIN, MOUSE;

AIRWAY RESISTANCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ACTIVATION; CELL INFILTRATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG TARGETING; FEMALE; GENE CLUSTER; IN VITRO STUDY; INFLAMMATION; INFLAMMATORY INFILTRATE; LUNG INJURY; MORTALITY; MOUSE; MOUSE MODEL; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RISK REDUCTION; SIGNAL TRANSDUCTION; SPLEEN CELL; SURVIVAL RATE; TOXIC SHOCK SYNDROME; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; C3H MOUSE; CELL CULTURE; CYTOLOGY; DRUG EFFECTS; IMMUNOLOGY; LUNG; METABOLISM; PATHOLOGY; SPLEEN;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CELLS, CULTURED; CYTOKINES; DRONABINOL; ENTEROTOXINS; FEMALE; LUNG; LUNG INJURY; MICE, INBRED C3H; MICRORNAS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; SPLEEN; T-LYMPHOCYTES, REGULATORY;

EID: 84924961972     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13026     Document Type: Article

References (71)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol 170: 1459-1581.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: Nuclear hormone receptors. Br J Pharmacol 170: 1652-1675.
3. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013c). The Concise Guide to PHARMACOLOGY 2013/14: Catalytic receptors. Br J Pharmacol 170: 1676-1705.
4. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013d). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
5. Alouf JE, Muller-Alouf H, (2003). Staphylococcal and streptococcal superantigens: molecular, biological and clinical aspects. Int J Med Microbiol 292: 429-440.
6. Bernard GR, Luce JM, Sprung CL, Rinaldo JE, Tate RM, Sibbald WJ, et al. (1987). High-dose corticosteroids in patients with the adult respiratory distress syndrome. N Engl J Med 317: 1565-1570.
7. Choi YW, Kotzin B, Herron L, Callahan J, Marrack P, Kappler J, (1989). Interaction of Staphylococcus aureus toxin 'superantigens' with human T cells. Proc Natl Acad Sci U S A 86: 8941-8945.
8. Dai R, Ahmed SA, (2011). MicroRNA, a new paradigm for understanding immunoregulation, inflammation, and autoimmune diseases. Transl Res 157: 163-179.
9. Darenberg J, Soderquist B, Normark BH, Norrby-Teglund A, (2004). Differences in potency of intravenous polyspecific immunoglobulin G against streptococcal and staphylococcal superantigens: implications for therapy of toxic shock syndrome. Clin Infect Dis 38: 836-842.
10. DaSilva L, Welcher BC, Ulrich RG, Aman MJ, David CS, Bavari S, (2002). Humanlike immune response of human leukocyte antigen-DR3 transgenic mice to staphylococcal enterotoxins: a novel model for superantigen vaccines. J Infect Dis 185: 1754-1760.
11. Davidson-Moncada J, Papavasiliou FN, Tam W, (2010). MicroRNAs of the immune system: roles in inflammation and cancer. Ann N Y Acad Sci 1183: 183-194.
12. DeVries AS, Lesher L, Schlievert PM, Rogers T, Villaume LG, Danila R, et al. (2011). Staphylococcal toxic shock syndrome 2000-2006: epidemiology, clinical features, and molecular characteristics. PLoS ONE 6: e22997.
13. Dinges MM, Orwin PM, Schlievert PM, (2000). Exotoxins of Staphylococcus aureus. Clin Microbiol Rev 13: 16-34, table of contents.
14. Do Y, McKallip RJ, Nagarkatti M, Nagarkatti PS, (2004). Activation through cannabinoid receptors 1 and 2 on dendritic cells triggers NF-kappaB-dependent apoptosis: novel role for endogenous and exogenous cannabinoids in immunoregulation. J Immunol 173: 2373-2382.
15. Faulkner L, Cooper A, Fantino C, Altmann DM, Sriskandan S, (2005). The mechanism of superantigen-mediated toxic shock: not a simple Th1 cytokine storm. J Immunol 175: 6870-6877.
16. Felder CC, Glass M, (1998). Cannabinoid receptors and their endogenous agonists. Annu Rev Pharmacol Toxicol 38: 179-200.
17. Goldbach-Mansky R, King PD, Taylor AP, Dupont B, (1992). A co-stimulatory role for CD28 in the activation of CD4+ T lymphocytes by staphylococcal enterotoxin B. Int Immunol 4: 1351-1360.
18. Greenhough A, Patsos HA, Williams AC, Paraskeva C, (2007). The cannabinoid delta(9)-tetrahydrocannabinol inhibits RAS-MAPK and PI3K-AKT survival signalling and induces BAD-mediated apoptosis in colorectal cancer cells. Int J Cancer 121: 2172-2180.
19. Guo H, Ingolia NT, Weissman JS, Bartel DP, (2010). Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 466: 835-840.
20. Hegde VL, Hegde S, Cravatt BF, Hofseth LJ, Nagarkatti M, Nagarkatti PS, (2008). Attenuation of experimental autoimmune hepatitis by exogenous and endogenous cannabinoids: involvement of regulatory T cells. Mol Pharmacol 74: 20-33.
21. Hegde VL, Nagarkatti M, Nagarkatti PS, (2010). Cannabinoid receptor activation leads to massive mobilization of myeloid-derived suppressor cells with potent immunosuppressive properties. Eur J Immunol 40: 3358-3371.
22. Hegde VL, Tomar S, Jackson A, Rao R, Yang X, Singh UP, et al. (2013). Distinct MicroRNA expression profile and targeted biological pathways in functional myeloid-derived suppressor cells induced by delta9-tetrahydrocannabinol in vivo: regulation of CCAAT/enhancer-binding protein alpha by microRNA-690. J Biol Chem 288: 36810-36826.
23. Hurley JM, Shimonkevitz R, Hanagan A, Enney K, Boen E, Malmstrom S, et al. (1995). Identification of class II major histocompatibility complex and T cell receptor binding sites in the superantigen toxic shock syndrome toxin 1. J Exp Med 181: 2229-2235.
24. Huzella LM, Buckley MJ, Alves DA, Stiles BG, Krakauer T, (2009). Central roles for IL-2 and MCP-1 following intranasal exposure to SEB: a new mouse model. Res Vet Sci 86: 241-247.
25. Jamontt JM, Molleman A, Pertwee RG, Parsons ME, (2010). The effects of Delta-tetrahydrocannabinol and cannabidiol alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis. Br J Pharmacol 160: 712-723.
26. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: Reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
27. Kissner TL, Ruthel G, Alam S, Ulrich RG, Fernandez S, Saikh KU, (2011). Activation of MyD88 signaling upon staphylococcal enterotoxin binding to MHC class II molecules. PLoS ONE 6: e15985.
28. Klein TW, (2005). Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol 5: 400-411.
29. Klein TW, Newton C, Zhu W, Daaka Y, Friedman H, (1995). delta 9-Tetrahydrocannabinol, cytokines, and immunity to Legionella pneumophila. Proc Soc Exp Biol Med 209: 205-212.
30. Krakauer T, (2013). Update on staphylococcal superantigen-induced signaling pathways and therapeutic interventions. Toxins (Basel) 5: 1629-1654.
31. Krakauer T, Buckley M, (2006). Dexamethasone attenuates staphylococcal enterotoxin B-induced hypothermic response and protects mice from superantigen-induced toxic shock. Antimicrob Agents Chemother 50: 391-395.
32. Krakauer T, Buckley M, (2012). Intranasal rapamycin rescues mice from staphylococcal enterotoxin B-induced shock. Toxins (Basel) 4: 718-728.
33. Krakauer T, Buckley M, Issaq HJ, Fox SD, (2010). Rapamycin protects mice from staphylococcal enterotoxin B-induced toxic shock and blocks cytokine release in vitro and in vivo. Antimicrob Agents Chemother 54: 1125-1131.
34. Larkin EA, Carman RJ, Krakauer T, Stiles BG, (2009). Staphylococcus aureus: the toxic presence of a pathogen extraordinaire. Curr Med Chem 16: 4003-4019.
35. Larkin EA, Stiles BG, Ulrich RG, (2010). Inhibition of toxic shock by human monoclonal antibodies against staphylococcal enterotoxin B. PLoS ONE 5: e13253.
36. Leelawat S, Leelawat K, Narong S, Matangkasombut O, (2010). The dual effects of delta(9)-tetrahydrocannabinol on cholangiocarcinoma cells: anti-invasion activity at low concentration and apoptosis induction at high concentration. Cancer Invest 28: 357-363.
37. Lindsay MA, (2008). microRNAs and the immune response. Trends Immunol 29: 343-351.
38. Linsley PS, Ledbetter JA, (1993). The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol 11: 191-212.
39. Liu SQ, Jiang S, Li C, Zhang B, Li QJ, (2014). miR-17-92 cluster targets phosphatase and tensin homology and ikaros family zinc finger 4 to promote TH17-mediated inflammation. J Biol Chem 289: 12446-12456.
40. Lyman WD, Sonett JR, Brosnan CF, Elkin R, Bornstein MB, (1989). Delta 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis. J Neuroimmunol 23: 73-81.
41. Mandal M, Kim S, Younes MN, Jasser SA, El-Naggar AK, Mills GB, et al. (2005). The Akt inhibitor KP372-1 suppresses Akt activity and cell proliferation and induces apoptosis in thyroid cancer cells. Br J Cancer 92: 1899-1905.
42. Matthys P, Mitera T, Heremans H, Van Damme J, Billiau A, (1995). Anti-gamma interferon and anti-interleukin-6 antibodies affect staphylococcal enterotoxin B-induced weight loss, hypoglycemia, and cytokine release in D-galactosamine-sensitized and unsensitized mice. Infect Immun 63: 1158-1164.
43. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
44. Meduri GU, Headley AS, Golden E, Carson SJ, Umberger RA, Kelso T, et al. (1998). Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. JAMA 280: 159-165.
45. Merkenschlager M, von Boehmer H, (2010). PI3 kinase signalling blocks Foxp3 expression by sequestering Foxo factors. J Exp Med 207: 1347-1350.
46. Miethke T, Wahl C, Heeg K, Echtenacher B, Krammer PH, Wagner H, (1992). T cell-mediated lethal shock triggered in mice by the superantigen staphylococcal enterotoxin B: critical role of tumor necrosis factor. J Exp Med 175: 91-98.
47. Nagarkatti M, Rieder SA, Hegde VL, Kanada S, Nagarkatti P, (2010). Do cannabinoids have a therapeutic role in transplantation? Trends Pharmacol Sci 31: 345-350.
48. Nagarkatti P, Pandey R, Rieder SA, Hegde VL, Nagarkatti M, (2009). Cannabinoids as novel anti-inflammatory drugs. Future Med Chem 1: 1333-1349.
49. O'Connell RM, Rao DS, Baltimore D, (2012). microRNA regulation of inflammatory responses. Annu Rev Immunol 30: 295-312.
50. Olive V, Bennett MJ, Walker JC, Ma C, Jiang I, Cordon-Cardo C, et al. (2009). miR-19 is a key oncogenic component of mir-17-92. Genes Dev 23: 2839-2849.
51. Olive V, Jiang I, He L, (2010). mir-17-92, a cluster of miRNAs in the midst of the cancer network. Int J Biochem Cell Biol 42: 1348-1354.
52. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-1106.
53. Rao R, Nagarkatti P, Nagarkatti M, (2014). Staphylococcal enterotoxin B (SEB) -induced microRNA-155 targets suppressor of cytokine signaling-1 (SOCS1) to promote acute inflammatory lung injury. Infect Immun 82: 2971-2979.
54. Reagan-Shaw S, Nihal M, Ahmad N, (2008). Dose translation from animal to human studies revisited. FASEB J 22: 659-661.
55. Rieder SA, Nagarkatti P, Nagarkatti M, (2011). CD1d-independent activation of invariant natural killer T cells by staphylococcal enterotoxin B through major histocompatibility complex class II/T cell receptor interaction results in acute lung injury. Infect Immun 79: 3141-3148.
56. Rieder SA, Nagarkatti P, Nagarkatti M, (2012). Multiple anti-inflammatory pathways triggered by resveratrol lead to amelioration of staphylococcal enterotoxin B-induced lung injury. Br J Pharmacol 167: 1244-1258.
57. Saeed AI, Rieder SA, Price RL, Barker J, Nagarkatti P, Nagarkatti M, (2012). Acute lung injury induced by Staphylococcal enterotoxin B: disruption of terminal vessels as a mechanism of induction of vascular leak. Microsc Microanal 18: 445-452.
58. Sasaki K, Kohanbash G, Hoji A, Ueda R, McDonald HA, Reinhart TA, et al. (2010). miR-17-92 expression in differentiated T cells-implications for cancer immunotherapy. J Transl Med 8: 17.
59. Sauer S, Bruno L, Hertweck A, Finlay D, Leleu M, Spivakov M, et al. (2008). T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc Natl Acad Sci U S A 105: 7797-7802.
60. Savransky V, Rostapshov V, Pinelis D, Polotsky Y, Korolev S, Komisar J, et al. (2003). Murine lethal toxic shock caused by intranasal administration of staphylococcal enterotoxin B. Toxicol Pathol 31: 373-378.
61. Shin I, Yakes FM, Rojo F, Shin NY, Bakin AV, Baselga J, et al. (2002). PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. Nat Med 8: 1145-1152.
62. Sonkoly E, Pivarcsi A, (2009). Advances in microRNAs: implications for immunity and inflammatory diseases. J Cell Mol Med 13: 24-38.
63. Srivastava MD, Srivastava BI, Brouhard B, (1998). Delta9 tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells. Immunopharmacology 40: 179-185.
64. Sun F, Fu H, Liu Q, Tie Y, Zhu J, Xing R, et al. (2008). Downregulation of CCND1 and CDK6 by miR-34a induces cell cycle arrest. FEBS Lett 582: 1564-1568.
65. Trede NS, Tsytsykova AV, Chatila T, Goldfeld AE, Geha RS, (1995). Transcriptional activation of the human TNF-alpha promoter by superantigen in human monocytic cells: role of NF-kappa B. J Immunol 155: 902-908.
66. Tsang WP, Kwok TT, (2009). The miR-18a∗ microRNA functions as a potential tumor suppressor by targeting on K-Ras. Carcinogenesis 30: 953-959.
67. Tsytsykova AV, Goldfeld AE, (2000). Nuclear factor of activated T cells transcription factor NFATp controls superantigen-induced lethal shock. J Exp Med 192: 581-586.
68. Ulrich RG, Sidell S, Taylor TJ, Wilhelmsen CL, Franz DR, (2001). Textbook of military medicine: medical aspects of chemical and biological warfare. Office of The Surgeon General, Department of the Army, United States of America.
69. Wajanaponsan N, Reade MC, Milbrandt EB, (2007). Steroids in late ARDS? Crit Care 11: 310.
70. Wu T, Wieland A, Araki K, Davis CW, Ye L, Hale JS, et al. (2012). Temporal expression of microRNA cluster miR-17-92 regulates effector and memory CD8+ T-cell differentiation. Proc Natl Acad Sci U S A 109: 9965-9970.
71. Xiao C, Srinivasan L, Calado DP, Patterson HC, Zhang B, Wang J, et al. (2008). Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol 9: 405-414.